Antiangiogenic VEGF‐TKIs have been used as a first‐line treatment option for RCC over the past 20 years and can greatly improve PFS and OS in patients with locally advanced or distant metastases.16 The gene discussed is VEGFA; the disease is renal cell carcinoma.